Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Afmedica Inc.

Division of Angiotech Pharmaceuticals Inc.

Latest From Afmedica Inc.

Breaking the Surgical Adhesion Barrier

Post-surgical adhesions occur almost any time a surgeon opens up a body cavity; in intra-abdominal surgery, for example, they form 85-90% of the time. But after a decade of trying, the medical device industry has only two adhesion prevention products to show for its efforts, and both products have drawbacks that have limited their market penetration. A new generation of companies--Confluent Surgical, Angiotech Pharmaceuticals, FzioMed, Sentrx Surgical, Afmedica, Kytogenics Pharmaceuticals, and ARC Pharmaceuticals, hope to profit from years of learning in the field to get new and improved products into the hands of surgeons .
Medical Device Combination Products

Vascular Architects: Going Against the Peripheral Flow

With most peripheral device companies focusing on interventionalists, Vascular Architects is changing course to make the forgotten vascular surgeon their primary customer.
Medical Device Strategy

Afmedica Inc.

It's not much of a stretch for companies to apply to other surgical markets the concepts that made drug-eluting stents such an overnight success. The overhealing response that characterizes in-stent restenosis is at the heart of many other processes that limit the long-term success of surgical interventions. In fact, Afmedica Inc. is building a drug plus device platform for vascular surgery around sirolimus, the very same drug that enabled Johnson & Johnson to be the first company to demonstrate that its drug-eluting stent prevents restenosis. Afmedica has built an IP estate around the use of the drug on the outside of vessels, where, in combination with non-inflammatory polymers, it might help reduce the failure of vascular access grafts for dialysis, prevent the closure of peripheral bypass grafts, and prevent surgical adhesions in abdominal surgery.
BioPharmaceutical Medical Device

Start-Up Previews (11/04)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Biotechs Battle Bacteria, features profiles of AureoGen Biosciences, Biovertis, Inimex Pharmaceuticals and Prolysis. Plus these Start-Ups across Health Care: Afmedica, Intercept Pharmaceuticals and MAP Pharmaceuticals.
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Angiotech Pharmaceuticals Inc.
  • Senior Management
  • Eli Thomssen, CBO
  • Contact Info
  • Afmedica Inc.
    Phone: (269) 349-8999
    259 E. Michigan Ave.
    Ste. 409
    Kalamazoo, MI 49007